会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明授权
    • CNP analog peptides and their use
    • CNP类似物及其用途
    • US5434133A
    • 1995-07-18
    • US828450
    • 1992-01-31
    • Shoji TanakaYoshiharu MinamitakeYasuo KitajimaMayumi FuruyaHisayuki Matsuo
    • Shoji TanakaYoshiharu MinamitakeYasuo KitajimaMayumi FuruyaHisayuki Matsuo
    • A61K38/22A61K38/00A61P43/00C07K7/08C07K14/575C07K14/58C12N15/16C07K14/00A61K38/16A61K38/17C07K14/435
    • C07K14/58A61K38/00Y02P20/55
    • Novel peptides represented by the general formula: ##STR1## and physiologically acceptable acid addition salts thereof; where (A) represents H-, H-Gly, H-Lys-Gly, H-Ser-Lys-Gly, H-Leu-Ser-Lys-Gly, H-Gly-Leu-Ser-Lys-Gly, H-ser, H-Ser-Ser, H-Arg-Ser-Ser, H-Arg-Arg-Ser-Ser, H-Leu-Arg-Arg-Ser-Ser, H-Ser-Leu-Arg-Arg-Ser-Ser;(B) represents H-Cys or Pmp;(C) represents Phe-, pCl-Phe, pF-Phe, pNO.sub.2 -Phe or Cha;(D) represents Ile, Val, Aib, tLeu, Gly or Leu;(E) represents Lys or Arg;(F) represents Ile, Leu or Met;(G) represents Ser or Ala;(H) represents Met or Gln;(I) represents --OH, -Asn-OH, -Asn-Ser-OH, -Asn-Ser-Phe-OH, -Asn-Ser-Phe-Arg-OH or -Asn-Ser-Phe-Arg-Tyr-OH; and the symbol " . . . " represents a disulfide bond;provided that 1) .alpha.-hANP, 2) .alpha.-hANP (7-28) and 3) CNP-22 are excluded from the scope of that general formula.Also disclosed are agents for suppressing the growth of vascular smooth muscle cells that contains those peptides as effective ingredients.
    • 由通式表示的新肽:其加成盐; 其中(A)表示H,H-Gly,H-Lys-Gly,H-Ser-Lys-Gly,H-Leu-Ser-Lys-Gly,H-Gly-Leu-Ser-Lys-Gly, Ser,H-Ser-Ser,H-Arg-Ser-Ser,H-Arg-Arg-Ser-Ser,H-Leu-Arg-Arg-Ser-Ser,H-Ser-Leu-Arg-Arg- 塞尔 (B)代表H-Cys或Pmp; (C)表示Phe-,pCl-Phe,pF-Phe,pNO2-Phe或Cha; (D)代表Ile,Val,Aib,tLeu,Gly或Leu; (E)表示Lys或Arg; (F)表示Ile,Leu或Met; (G)表示Ser或Ala; (H)表示Met或Gln; (I)表示-OH,-Asn-OH,-Asn-Ser-OH,-Asn-Ser-Phe-OH,-Asn-Ser-Phe-Arg-OH或-Asn-Ser-Phe-Arg-Tyr- 哦; 符号“......”代表二硫键; 条件是1)α-hANP,2)α-hANP(7-28)和3)CNP-22被排除在该通式的范围之外。 还公开了抑制含有那些肽作为有效成分的血管平滑肌细胞生长的药剂。
    • 10. 发明授权
    • Therapeutics for thrombocytopenia
    • 血小板减少症治疗
    • US6040335A
    • 2000-03-21
    • US849887
    • 1997-07-31
    • Masayuki SaitohYasuo KitajimaNorio IwasawaKenju MiuraMunetada HaruyamaJunko Hashino
    • Masayuki SaitohYasuo KitajimaNorio IwasawaKenju MiuraMunetada HaruyamaJunko Hashino
    • C07F9/655A61K31/365C07D309/02
    • C07F9/6552
    • Compounds represented by the general formula (I) or pharmacologically acceptable salts thereof: ##STR1## (where R is a group --NHCHR.sub.1 R.sub.2, --N(CHR.sub.1 R.sub.2).sub.2, --N(CHR.sub.1 R.sub.2)CHR.sub.3 R.sub.4, --N.sup.+ (CHR.sub.1 R.sub.2).sub.3, --N.sup.+ (CHR.sub.1 R.sub.2).sub.2 CHR.sub.3 R.sub.4 or --N.sup.+ (CHR.sub.1 R.sub.2)(CHR.sub.3 R.sub.4)CHR.sub.5 R.sub.6 (where R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6, which may be the same or different, are each a hydrogen atom, an alkyl group, an alkenyl group, an aryl group or an aralkyl group, or an alkyl, alkenyl, aryl or aralkyl group which is substituted by at least one substituent selected from the group consisting of a halogen atom, a hydroxyl group, a lower alkoxy group, a lower alkylacyloxy group, a lower alkylacyl group, a lower alkoxycarbonyl group, a nitro group, a cyano group and a heterocyclic group, with CHR.sub.1 R.sub.2, CHR.sub.3 R.sub.4 or CHR.sub.5 R.sub.6 optionally forming a cyclic alkyl group, provided that when R is --N(CHR.sub.1 R.sub.2)CHR.sub.3 R.sub.4, --N.sup.+ (CHR.sub.1 R.sub.2).sub.2 CHR.sub.3 R.sub.4 or --N.sup.+ (CHR.sub.1 R.sub.2)(CHR.sub.3 R.sub.4)CHR.sub.5 R.sub.6, CHR.sub.1 R.sub.2, CHR.sub.3 R.sub.4 and CHR.sub.5 R.sub.6 are different groups); therapeutics for thrombocytopenia containing them as an effective ingredient; as well as intermediates for their synthesis and processes for producing them.
    • PCT No.PCT / JP96 / 03008 Sec。 371日期1997年7月31日 102(e)1997年7月31日PCT PCT 1996年10月17日PCT公布。 出版物WO97 / 14704 日期:1997年04月24日由通式(I)表示的化合物或其药理学上可接受的盐:(其中R为基团-NHCHR1R2,-N(CHR1R2)2,-N(CHR1R2)CHR3R4,-N +(CHR1R2) -N +(CHR 1 R 2)2 CHR 3 R 4或-N +(CHR 1 R 2)(CHR 3 R 4)CHR 5 R 6(其中R 1,R 2,R 3,R 4,R 5和R 6可以相同或不同,分别为氢原子,烷基, 基团,芳基或芳烷基,或被选自卤素原子,羟基,低级烷氧基,低级烷基酰氧基中的至少一个取代基取代的烷基,烯基,芳基或芳烷基 基团,低级烷基酰基,低级烷氧基羰基,硝基,氰基和杂环基,与任选形成环状烷基的CHR 1 R 2,CHR 3 R 4或CHR 5 R 6,条件是当R为-N(CHR 1 R 2)CHR 3 R 4时, N +(CHR1R2)2CHR3R4或-N +(CHR1R2)(CHR3R4)CHR5R6,CHR1R2,CHR3R4和CHR5R6是不同的组);含有血小板减少症的治疗剂 有益成分; 以及它们的合成中间体及其制备方法。